<DOC>
	<DOCNO>NCT00094107</DOCNO>
	<brief_summary>This Phase 2 study conduct multiple center United States France . Patients melanoma spread part body ( i.e. , metastatic ) eligible participate . Patients must disease treat 1 prior treatment metastatic disease ( prior adjuvant treatment localize disease count prior treatment metastatic disease ) . The purpose study test whether angiogenesis inhibitor AG-013736 effective treatment metastatic melanoma show number patient study experience significant durable tumor shrinkage .</brief_summary>
	<brief_title>Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Skin Neoplasms</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<mesh_term>Angiogenesis Inhibitors</mesh_term>
	<criteria>Histologically document melanoma metastases No 1 prior systemic therapy metastatic disease ( prior adjuvant therapy interferon count prior therapy metastatic disease ) History hemoptysis ( cough blood ) Brain metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>melanoma</keyword>
	<keyword>antiangiogenesis</keyword>
</DOC>